Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD)
encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to …

3606 Background: Fluoropyrimidines, although generally well tolerated, can induce life-
threatening toxicity. The major known cause of intolerance is deficiency of the detoxifying …

Objectives Genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene are
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …

Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …

Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe
fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are …

PURPOSE Fluoropyrimidine-related toxicity and mortality risk increases significantly in
patients carrying certain DPYD genetic variants with standard dosing. We implemented …

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is
gaining importance as predictors of fluoropyrimidine-associated toxicity. The …

Background Fluoropyrimidine drugs are widely used in chemotherapy to treat solid tumors.
However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene …

Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting step in fluoropyrimidines
metabolism. Currently, genotype-guided fluoropyrimidine dosing is recommended for four …

Abstract Introduction In April 2019, French authorities mandated dihydropyrimidine
dehydrogenase (DPD) screening, specifically testing uracilemia, to mitigate the risk of …